A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)
| dc.contributor.author | Van Vollenhoven, Ronald F. | |
| dc.contributor.author | Voskuyl, Alexandre E. | |
| dc.contributor.author | Bertsias, George | |
| dc.contributor.author | Aranow, Cynthia | |
| dc.contributor.author | Aringer, Martin | |
| dc.contributor.author | Arnaud, Laurent | |
| dc.contributor.author | Askanase, Anca | |
| dc.contributor.author | Balá ová, Petra | |
| dc.contributor.author | Bonfa, Eloisa | |
| dc.contributor.author | Bootsma, Hendrika | |
| dc.contributor.author | Boumpas, Dimitrios | |
| dc.contributor.author | Bruce, Ian N. | |
| dc.contributor.author | Cervera i Segura, Ricard, 1960- | |
| dc.contributor.author | Clarke, Ann E. | |
| dc.contributor.author | Coney, Cindy | |
| dc.contributor.author | Costedoat-Chalumeau, Nathalie | |
| dc.contributor.author | Czirják, László | |
| dc.contributor.author | Derksen, R. H. W. M. | |
| dc.contributor.author | Doria, Andrea | |
| dc.contributor.author | Dörner, Thomas | |
| dc.contributor.author | Fischer-Betz, Rebecca | |
| dc.contributor.author | Fritsch-Stork, Ruth | |
| dc.contributor.author | Gordon, Caroline | |
| dc.contributor.author | Graninger, Winfried | |
| dc.contributor.author | Györi, Noémi | |
| dc.contributor.author | Houssiau, Frédéric A. | |
| dc.contributor.author | Isenberg, David | |
| dc.contributor.author | Jacobsen, Søren | |
| dc.contributor.author | Jayne, David | |
| dc.contributor.author | Kuhn, Annegret | |
| dc.contributor.author | Le Guern, Véronique | |
| dc.contributor.author | Lerstrøm, Kirsten | |
| dc.contributor.author | Levy, Roger A. | |
| dc.contributor.author | Machado-Ribeiro, Francinne | |
| dc.contributor.author | Mariette, Xavier | |
| dc.contributor.author | Missaykeh, Jamil | |
| dc.contributor.author | Morand, Eric | |
| dc.contributor.author | Mosca, Marta | |
| dc.contributor.author | Inanc, Murat | |
| dc.contributor.author | Navarra, Sandra | |
| dc.date.accessioned | 2018-06-22T08:07:58Z | |
| dc.date.available | 2018-06-22T08:07:58Z | |
| dc.date.issued | 2016-11-24 | |
| dc.date.updated | 2018-06-22T08:07:58Z | |
| dc.description.abstract | Objectives Treat-to-target recommendations have identified 'remission' as a target in systemic lupus erythematosus (SLE), but recognise that there is no universally accepted definition for this. Therefore, we initiated a process to achieve consensus on potential definitions for remission in SLE. Methods An international task force of 60 specialists and patient representatives participated in preparatory exercises, a face-to-face meeting and follow-up electronic voting. The level for agreement was set at 90%. Results The task force agreed on eight key statements regarding remission in SLE and three principles to guide the further development of remission definitions: 1. Definitions of remission will be worded as follows: remission in SLE is a durable state characterised by . (reference to symptoms, signs, routine labs). 2. For defining remission, a validated index must be used, for example, clinical systemic lupus erythematosus disease activity index (SLEDAI)=0, British Isles lupus assessment group (BILAG) 2004 D/E only, clinical European consensus lupus outcome measure (ECLAM)=0; with routine laboratory assessments included, and supplemented with physician's global assessment. 3. Distinction is made between remission off and on therapy: remission off therapy requires the patient to be on no other treatment for SLE than maintenance antimalarials; and remission on therapy allows patients to be on stable maintenance antimalarials, low-dose corticosteroids (prednisone ≤5 mg/day), maintenance immunosuppressives and/or maintenance biologics. The task force also agreed that the most appropriate outcomes (dependent variables) for testing the prognostic value (construct validity) of potential remission definitions are: death, damage, flares and measures of health-related quality of life. Conclusions The work of this international task force provides a framework for testing different definitions of remission against long-term outcomes. | |
| dc.format.extent | 8 p. | |
| dc.format.mimetype | application/pdf | |
| dc.identifier.idgrec | 678610 | |
| dc.identifier.issn | 0003-4967 | |
| dc.identifier.pmid | 27884822 | |
| dc.identifier.uri | https://hdl.handle.net/2445/123199 | |
| dc.language.iso | eng | |
| dc.publisher | BMJ Publishing Group | |
| dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1136/annrheumdis-2016-209519 | |
| dc.relation.ispartof | Annals of the Rheumatic Diseases, 2016, vol. 76, num. 3, p. 554-561 | |
| dc.relation.uri | https://doi.org/10.1136/annrheumdis-2016-209519 | |
| dc.rights | (c) BMJ Publishing Group, 2016 | |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | |
| dc.source | Articles publicats en revistes (Medicina) | |
| dc.subject.classification | Lupus eritematós | |
| dc.subject.classification | Malalties autoimmunitàries | |
| dc.subject.classification | Farmacologia | |
| dc.subject.classification | Estudi de casos | |
| dc.subject.other | Lupus erythematosus | |
| dc.subject.other | Autoimmune diseases | |
| dc.subject.other | Pharmacology | |
| dc.subject.other | Case studies | |
| dc.title | A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS) | |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:eu-repo/semantics/publishedVersion |
Fitxers
Paquet original
1 - 1 de 1